Mitsubishi UFJ Trust & Banking Corp Grows Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Mitsubishi UFJ Trust & Banking Corp grew its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBHFree Report) by 0.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 122,429 shares of the medical equipment provider’s stock after acquiring an additional 259 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp owned about 0.06% of Zimmer Biomet worth $13,739,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in ZBH. Clear Street Markets LLC purchased a new position in shares of Zimmer Biomet during the fourth quarter valued at approximately $27,000. Horizon Bancorp Inc. IN grew its position in Zimmer Biomet by 1,483.3% in the 2nd quarter. Horizon Bancorp Inc. IN now owns 190 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 178 shares during the last quarter. OLD Point Trust & Financial Services N A purchased a new stake in Zimmer Biomet in the second quarter worth $32,000. Dark Forest Capital Management LP bought a new stake in shares of Zimmer Biomet during the first quarter worth $35,000. Finally, WealthPLAN Partners LLC purchased a new stake in shares of Zimmer Biomet during the second quarter valued at $39,000. 87.48% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Stock Performance

Shares of Zimmer Biomet stock opened at $125.85 on Tuesday. The company has a 50 day moving average price of $121.57 and a 200 day moving average price of $117.25. The firm has a market capitalization of $26.30 billion, a P/E ratio of 25.74, a PEG ratio of 2.23 and a beta of 1.03. The company has a quick ratio of 0.78, a current ratio of 1.61 and a debt-to-equity ratio of 0.39. Zimmer Biomet Holdings, Inc. has a 52 week low of $102.00 and a 52 week high of $149.25.

Zimmer Biomet (NYSE:ZBHGet Free Report) last posted its quarterly earnings data on Thursday, February 8th. The medical equipment provider reported $2.20 EPS for the quarter, topping the consensus estimate of $2.15 by $0.05. Zimmer Biomet had a net margin of 13.85% and a return on equity of 12.79%. The business had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.93 billion. During the same period in the previous year, the firm posted $1.88 earnings per share. The business’s revenue for the quarter was up 6.3% compared to the same quarter last year. Sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.03 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, January 31st. Stockholders of record on Wednesday, December 27th were paid a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.76%. The ex-dividend date was Tuesday, December 26th. Zimmer Biomet’s payout ratio is 19.63%.

Analyst Ratings Changes

A number of brokerages recently weighed in on ZBH. JMP Securities decreased their price objective on shares of Zimmer Biomet from $160.00 to $140.00 and set a “market outperform” rating for the company in a report on Monday, November 13th. Royal Bank of Canada reiterated an “outperform” rating and issued a $140.00 price target on shares of Zimmer Biomet in a report on Friday. JPMorgan Chase & Co. lifted their target price on Zimmer Biomet from $115.00 to $125.00 and gave the company a “neutral” rating in a research report on Friday. Truist Financial increased their price target on Zimmer Biomet from $133.00 to $135.00 and gave the stock a “hold” rating in a research report on Friday. Finally, Morgan Stanley lifted their price objective on Zimmer Biomet from $120.00 to $125.00 and gave the company an “equal weight” rating in a report on Monday, December 4th. Two analysts have rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $138.63.

Check Out Our Latest Research Report on ZBH

About Zimmer Biomet

(Free Report)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Featured Articles

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.